To study whether BCL-2 inhibition is therapeutically relevant in the context of PRMT5-targeted therapy in lymphoma, we used venetoclax, a potent and selective BCL-2 inhibitor, which is FDA-approved for the treatment of patients with chronic lymphocytic leukemia and small lymphocytic leukemia36. The gene discussed is BCL2; the disease is lymphoma.